title: Intracoronary adenosine to prevent myonecrosis in patients with stable angina undergoing percutaneous interventions: a double-blinded randomized controlled trial.
abstract: BACKGROUND
  Significant elevation of cardiac biomarkers after percutaneous coronary intervention (PCI) is associated with increased mortality. However, clinical importance of lesser degrees of cardiac enzyme elevation has not been well understood. Multiple factors might have an etiologic role, and the incidence of myonecrosis has not changed dramatically despite pharmacological and technological advances in PCI. The aim of this study was to evaluate the role of intracoronary (IC) Adenosine in preventing the elevation of cardiac enzymes as a marker of myonecrosis after PCI in patients with chronic stable angina.
  
  
  METHODS
  Two hundred sixty patients with chronic stable angina who were candidates for PCI were randomly assigned to double-blinded pretreatment with IC Adenosine or placebo before crossing of the guide wire. The patients were observed during the hospital course, and blood samples were obtained in standard intervals after the intervention for cardiac biomarkers. The primary end point of this study was post-PCI myonecrosis, and secondary end point was safety of IC Adenosine administration in the setting of PCI in patients with chronic stable angina.
  
  
  RESULTS
  Of the 260 patients, who were initially randomized, finally 83 patients were analyzed in the placebo and 96 in the Adenosine arms. The study patients were comparable in clinical and angiographic characteristics. The mean of the patients' age was 57.3 years (range = 35 to 79 years), and 71.5% were male. There were no differences in the mean serum cardiac biomarkers between the study groups (mean creatine kinase-MB [CK.MB] level of 29.5 ± 14.5 IU/L in the placebo group and 31.5 ± 18.5 IU/L in the control group; p value = 0.41; mean cardiac troponin I (cTnI) level of 0.097 ± 0.178 μg/L in the placebo group and 0.167 ± 0.5 μg/L in the control group; p value = 0.24).
  
  
  CONCLUSIONS
  Despite promising results in primary PCI, our study showed that a strategy of IC Adenosine pretreatment is not beneficial in reducing post-PCI myonecrosis in patients with chronic stable angina and should not be routinely used.
authors: Cardiovascular Intervention Research Center, Rajaie Cardiovascular, Medical and Research Center, Tehran University of Medical Sciences, Tehran, Iran.
authors: Hamid Reza
authors: HR
authors: Sanati
authors: Reza
authors: R
authors: Ghanavati
authors: Ali
authors: A
authors: Zahedmehr
authors: Farshad
authors: F
authors: Shakerian
authors: Hooman
authors: H
authors: Bakhshandeh
authors: Ata
authors: A
authors: Firouzi
authors: Reza
authors: R
authors: Kiani
keywords: Adenosine; Angina, stable; Percutaneous coronary intervention
references: Eur Heart J. 2006 Oct;27(20):2400-5
references: 16782719
references: Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1633-40
references: 15772334
references: Blood. 2002 Apr 15;99(8):2794-800
references: 11929768
references: Eur Heart J. 2005 Dec;26(23):2493-519
references: 16176941
references: Circulation. 1988 Dec;78(6):1323-34
references: 2973376
references: Circulation. 2004 Aug 10;110(6):674-8
references: 15277322
references: N Engl J Med. 1992 Jan 2;326(1):10-6
references: 1345754
references: Circulation. 2000 Jul 25;102(4):386-91
references: 10908209
references: J Am Coll Cardiol. 2005 Jun 7;45(11):1775-80
references: 15936605
references: Circ Res. 1989 Nov;65(5):1296-305
references: 2805245
references: Circulation. 1996 Oct 1;94(7):1528-36
references: 8840840
references: Eur Heart J. 2004 Oct;25(20):1822-8
references: 15474697
references: Circulation. 1987 Nov;76(5):1135-45
references: 3664998
references: Am J Cardiol. 2004 Jan 1;93(1):18-23
references: 14697460
references: Circulation. 2002 Sep 3;106(10):1205-10
references: 12208794
references: Catheter Cardiovasc Interv. 2000 Sep;51(1):27-31; discussion 32
references: 10973014
references: Am J Cardiol. 2004 Jul 1;94(1):9-13
references: 15219500
references: BMJ. 2000 Jul 8;321(7253):73-7
references: 10884254
references: Circulation. 2000 Feb 8;101(5):570-80
references: 10662756
references: J Am Coll Cardiol. 2004 Mar 17;43(6):1122-6
references: 15028378
references: J Am Coll Cardiol. 1998 Feb;31(2):241-51
references: 9462562
references: Eur Heart J. 2002 Jun;23(11):869-76
references: 12042008
references: J Am Coll Cardiol. 1999 Nov 15;34(6):1711-20
references: 10577561
references: Int J Cardiol. 2003 Dec;92(2-3):285-93
references: 14659867
references: Am J Health Syst Pharm. 1998 Mar 1;55(5):466-70
references: 9522931
references: Circulation. 1999 Jan 26;99(3):348-53
references: 9918520
references: Circulation. 2004 Sep 7;110(10):1213-8
references: 15337691
references: J Am Coll Cardiol. 2008 Jan 15;51(2):172-209
references: 18191745
references: J Am Coll Cardiol. 1991 Mar 1;17(3):621-6
references: 1993778
references: Circulation. 2000 May 9;101(18):2154-9
references: 10801755
references: J Am Coll Cardiol. 1993 Nov 1;22(5):1283-8
references: 8227781
references: Circulation. 2000 Feb 29;101(8):841-3
references: 10694520
references: Am J Cardiol. 1998 Dec 15;82(12):1445-50
references: 9874045